changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 20 September 2017
BTG plc (LSE: BTG), the global specialist healthcare company, announces that a Memorandum Opinion has been issued by the Court of Chancery of Delaware ruling against BTG in its previously announced litigation with Wellstat Therapeutics Corporation concerning the commercialisation of Vistogard®. The Court has found that BTG has breached the distribution agreement and that Wellstat is entitled to damages of $55.8m plus interest and costs.
BTG is surprised and disappointed by the Opinion and is considering options, which include appealing the ruling and level of damages awarded.
For further information contact
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.
Vistogard is a registered trademark of Wellstat Therapeutics Corporation.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com